Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus

•Excellent outcome with moxifloxacin/rifampin combination therapy in the treatment of early PJI caused by MSSA.•Moxifloxacin is an attractive agent in treatment of PJI.•Dose adjustments are not required in patients with renal insufficiency.•Moxifloxacin exhibits a high genetic barrier for resistance.•Moxifloxacin/rifampin may be used as an alternative for levofloxacin/rifampin in the treatment of early PJI caused by MSSA.